These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1207037)

  • 1. Solid intraperitoneal Landschütz tumour in mice: implications in cancer chemotherapy and immunology studies.
    Hod I; Zimber A; Gidoni D; Schonfeld S
    Lab Anim; 1975 Oct; 9(4):319-27. PubMed ID: 1207037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in production of solid Landhscütz tumours in BALB/c and ICR mice.
    Hod I; Zimber A; Gidoni D; Shaul Y
    Lab Anim; 1977 Jan; 11(1):51-2. PubMed ID: 839724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE EFFECT OF INTRAPERITONEAL INJECTION OF THORACIC DUCT LYMPHOCYTES FROM NORMAL AND IMMUNIZED RATS IN MICE INOCULATED WITH THE LANDSCHUTZ ASCITES TUMOUR.
    WOODRUFF MF; SYMES MO; ANDERSON NF
    Br J Cancer; 1963 Sep; 17(3):482-7. PubMed ID: 14062496
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of HSP47 during the transition from solid to ascitic form of Sarcoma 180 in vivo.
    Shirakami T; Tsuzuki T; Iijima H; Ishikawa Y; Kiyosuke YI; Morino M; Yoshimura M; Yoshikumi C
    In Vivo; 1995; 9(5):509-12. PubMed ID: 8900931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
    Hiramoto RN; Ghanta VK
    Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
    [No Abstract]   [Full Text] [Related]  

  • 6. Specificity of cell-mediated transplantation reactions. I. Studies with the technique of inhibition of migration and an assay of tumour immunity in vivo.
    Lake P; Sabbadini E; Sehon AH
    Immunology; 1974 Sep; 27(3):427-39. PubMed ID: 4137936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour and antimetastatic effect of genistein alone or combined with cyclophosphamide in mice transplanted with various tumours depends on the route of tumour transplantation.
    Wietrzyk J; Opolski A; Madej J; Radzikowski C
    In Vivo; 2000; 14(2):357-62. PubMed ID: 10836210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition and enhancement of the Landschütz ascites tumour with lymphoid cells.
    el-Hassan AM; Stuart AE
    J Pathol Bacteriol; 1966 Jan; 91(1):11-31. PubMed ID: 5941386
    [No Abstract]   [Full Text] [Related]  

  • 10. MCG101-AA, a new ascites tumour in C57 mice. 2. Protocol of vivo transplantation studies in comparison with the solid (SS) and solid ascites (AS) tumours.
    Hagmar B
    Acta Pathol Microbiol Scand A; 1974 May; 82(3):369-78. PubMed ID: 4853308
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of the immune response to transplantation antigens. II. The effects of heterologous antisera on the growth of tumour allografts in mice.
    Zola H
    Clin Exp Immunol; 1974 Mar; 16(3):461-7. PubMed ID: 4468850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of DEAE-dextran on tumour growth. (2). A). Effect of DEAE-dextran in vivo on the transplantable ascites tumour JBI in C3H/A mice. B). Action of dextran sulphate administered after inoculation of DEAE-dextran inhibited tumour cells.
    Thorling EB; Larsen B
    Acta Pathol Microbiol Scand; 1969; 75(2):237-46. PubMed ID: 5361350
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic response of human lung tumour xenografts to cyclophosphamide.
    Mattern J; Jaeger S; Wayss K; Volm M
    Anticancer Res; 1982; 2(6):355-8. PubMed ID: 7168553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance and susceptibility to tumours. II. An attempt to heal mice bearing the Bo4 tumour using transferred mice spleen cells.
    Dvorák R; Chlumecký J
    Neoplasma; 1969; 16(1):11-5. PubMed ID: 5786507
    [No Abstract]   [Full Text] [Related]  

  • 15. Peritoneal cell populations during tumour injection.
    De Heer E; De Groot JW; Den Otter W; Dullens HF
    Int J Tissue React; 1982; 4(1):81-90. PubMed ID: 7085002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative studies of the growth and rejection of allogeneic tumour cells in mouse cerebrospinal fluid. Elimination in the absence of H-2 differences.
    Doherty PC; Zinkernagel RM
    Clin Exp Immunol; 1975 Feb; 19(2):355-66. PubMed ID: 813923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Criteria associated with destruction of leukemia and solid tumor cells in animals.
    Skipper HE
    Cancer Res; 1967 Dec; 27(12):2636-45. PubMed ID: 6082300
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody response to ATPC+ascites tumour in mice rendered resistant by intravenous inoculation of liver cells.
    Pitzurra M; Marconi P
    Boll Ist Sieroter Milan; 1972; 51(5):393-404. PubMed ID: 4656954
    [No Abstract]   [Full Text] [Related]  

  • 19. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunogenicity of cyclophosphamide-treated tumor cells.
    Kawalec M; Skórski T; Hoser G
    Arch Immunol Ther Exp (Warsz); 1988; 36(3):345-50. PubMed ID: 3250356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.